The assessment of the beta-blocking activity of urapidil: A new method

M. J. Jamieson, S. H.D. Jackson, S. S. Patel, A. M.M. Shepherd, H. Galbraith, W. Stewart, P. H. Flanagan

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Urapidil is an antihypertensive vasodilator agent whose pharmacological action in man has not yet been fully defined. We have assessed the beta blocking activity of urapidil 15 mg and 30 mg i.v. in a single blind study of 10 healthy male volunteers. Urapidil at plasma concentrations in the same range as those shown to have antihypertensive affect did not significantly attenuate the chronotropic effect of isoproterenol. Propranolol 5 mg iv, the positive control, significantly shifted the isoproterenol dose-response curve to the right. We describe a new method of analyzing incomplete dose response curves whereby a linear terminal segment can be reproducibly defined.

Original languageEnglish (US)
Pages (from-to)149-154
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Issue number2
StatePublished - Mar 1986


  • urapidil
  • volunteers isoproterenol dose response analysis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The assessment of the beta-blocking activity of urapidil: A new method'. Together they form a unique fingerprint.

Cite this